BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 29334794)

  • 1. A look at the progress of treating pancreatic cancer over the past 20 years.
    Goess R; Friess H
    Expert Rev Anticancer Ther; 2018 Mar; 18(3):295-304. PubMed ID: 29334794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
    Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
    BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant and neoadjuvant therapy for resectable pancreatic adenocarcinoma.
    Sohal DPS
    Chin Clin Oncol; 2017 Jun; 6(3):26. PubMed ID: 28705003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant therapy for resectable and borderline resectable adenocarcinoma of the pancreas.
    Wolff RA
    Curr Drug Targets; 2012 Jun; 13(6):781-8. PubMed ID: 22458524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status of adjuvant therapy for pancreatic cancer.
    Katz MH; Fleming JB; Lee JE; Pisters PW
    Oncologist; 2010; 15(11):1205-13. PubMed ID: 21045189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant therapy versus upfront surgery for borderline-resectable pancreatic cancer.
    Han S; Choi SH; Choi DW; Heo JS; Han IW; Park DJ; Ryu Y
    Minerva Chir; 2020 Feb; 75(1):15-24. PubMed ID: 31115240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial.
    Jang JY; Han Y; Lee H; Kim SW; Kwon W; Lee KH; Oh DY; Chie EK; Lee JM; Heo JS; Park JO; Lim DH; Kim SH; Park SJ; Lee WJ; Koh YH; Park JS; Yoon DS; Lee IJ; Choi SH
    Ann Surg; 2018 Aug; 268(2):215-222. PubMed ID: 29462005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy.
    Wijetunga AR; Chua TC; Nahm CB; Pavlakis N; Clarke S; Chan DL; Diakos C; Maloney S; Ashrafi-Zadeh A; Kneebone A; Hruby G; Jamieson NB; Gill A; Mittal A; Samra JS
    Eur J Surg Oncol; 2021 Oct; 47(10):2543-2550. PubMed ID: 33952409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current standards and new innovative approaches for treatment of pancreatic cancer.
    Conroy T; Bachet JB; Ayav A; Huguet F; Lambert A; Caramella C; Maréchal R; Van Laethem JL; Ducreux M
    Eur J Cancer; 2016 Apr; 57():10-22. PubMed ID: 26851397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of palliative chemotherapy in advanced pancreatic cancer.
    Westphalen CB; Kruger S; Haas M; Heinemann V; Boeck S
    Expert Opin Drug Saf; 2016 Jul; 15(7):947-54. PubMed ID: 27070177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant strategies for pancreatic cancer.
    Evans DB; Wolff RA; Crane CH
    Oncology (Williston Park); 2001 Jun; 15(6):727-37; discussion 741-4, 747. PubMed ID: 11430206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial.
    Versteijne E; van Eijck CH; Punt CJ; Suker M; Zwinderman AH; Dohmen MA; Groothuis KB; Busch OR; Besselink MG; de Hingh IH; Ten Tije AJ; Patijn GA; Bonsing BA; de Vos-Geelen J; Klaase JM; Festen S; Boerma D; Erdmann JI; Molenaar IQ; van der Harst E; van der Kolk MB; Rasch CR; van Tienhoven G;
    Trials; 2016 Mar; 17(1):127. PubMed ID: 26955809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemoradiation for non-metastatic pancreatic cancer increases margin-negative and node-negative rates at resection.
    Berriochoa CA; Abdel-Wahab M; Leyrer CM; Khorana A; Matthew Walsh R; Kumar AMS
    J Dig Dis; 2017 Nov; 18(11):642-649. PubMed ID: 29055078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Future chemoradiation strategies in pancreatic cancer.
    Crane CH; Varadhachary G; Pisters PW; Evans DB; Wolff RA
    Semin Oncol; 2007 Aug; 34(4):335-46. PubMed ID: 17674962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1).
    Gao S; Zhu X; Shi X; Cao K; Bian Y; Jiang H; Wang K; Guo S; Zhang H; Jin G
    Radiat Oncol; 2019 Mar; 14(1):52. PubMed ID: 30917842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer?
    Kim R; Saif MW
    JOP; 2007 May; 8(3):279-88. PubMed ID: 17495356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant Treatment for Pancreatic Cancer.
    Raufi AG; Manji GA; Chabot JA; Bates SE
    Semin Oncol; 2019 Feb; 46(1):19-27. PubMed ID: 30630600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).
    Heinrich S; Pestalozzi B; Lesurtel M; Berrevoet F; Laurent S; Delpero JR; Raoul JL; Bachellier P; Dufour P; Moehler M; Weber A; Lang H; Rogiers X; Clavien PA
    BMC Cancer; 2011 Aug; 11():346. PubMed ID: 21831266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
    Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C
    Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer.
    Heinemann V; Haas M; Boeck S
    Ann Oncol; 2013 Oct; 24(10):2484-2492. PubMed ID: 23852311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.